Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

Global pharma major Lupin Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, with a Voluntary Action Indicated (VAI) status. The facility was inspected from May 7 to May 17, 2024. Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India, with a significant presence in various therapeutic areas and a leadership position in the cardiovascular, anti-diabetic, and respiratory segments. The company invested 7.8% of its revenue in research and development in FY24 and has 15 manufacturing sites, 7 research centers, and more than 20,000 professionals working globally.